Drug intelligence / Profile preview

erythromycin

Development stage
Approved
Lead developer
Eli Lilly
Modality
Small Molecules
Administration
Oral, Intravenous, Topical, Ophthalmic
01

Overview

Erythromycin is a macrolide antibiotic used to treat a wide range of bacterial infections, including respiratory tract infections, skin infections, diphtheria, pertussis (whooping cough), syphilis, pelvic inflammatory disease, and others[1][2][3][4][5]. It works primarily by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking aminoacyl translocation during translation[5]. This action is bacteriostatic but can be bactericidal at higher concentrations or against highly susceptible organisms. In addition to its antimicrobial effects, erythromycin acts as an agonist at motilin receptors in the gastrointestinal tract and can be used as a prokinetic agent to stimulate gastric emptying[5]. It was first discovered in 1952.

Brand names
E.E.S. 200E.E.S. 400E.E.S. GranulesErycErypedEryped 200Eryped200Eryped-200Eryped 400Eryped400Eryped-400ErythrocinErythrocin StearateIlosonePCE DispertabPCEEmgelRomycin
Other names
AbomacetinDumotrycinMephamycinEritromicina (Spanish/Italian)RobimycinTorlamicinaPantomicinaStiemycinTiprocinAcnesolDerimerDeripil
02

Targets

Bacterial 50S ribosomal subunitMLNR (Human motilin receptor)

Beyond the preview

Go deeper on erythromycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on erythromycin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call